臨床外科76巻13号

2021年12月発行

特集 Conversion surgeryアップデート がん種別の最新動向

神経内分泌腫瘍に対するconversion surgery

著者： 工藤篤¹ 村瀬芳樹¹ 赤星径一¹ 浅野大輔¹ 石川喜也¹ 小川康介¹ 小野宏晃¹ 田邉稔¹

所属機関： ¹東京医科歯科大学病院肝胆膵外科

ページ範囲：P.1536 - P.1541

【ポイント】
◆神経内分泌腫瘍の肝転移（NELM）における術前補助療法（NAC）の対象はNET-G3とNECとされている．
◆NACで使う薬剤はNET-G3がテモゾロミド（ストレプトゾシン）ベース，プラチナベース，放射性核種標識ペプチド療法（PRRT）などが候補と考えられている．
◆スニチニブを用いたconversion surgeryで良好な成績が報告された．
◆機能性腫瘍はNELMの絶対的手術適応であり，薬物ではホルモン症状のコントロールが困難である．

参考文献

1）Yao JC, Hassan M, Phan A, et al：One hundred years after “carcinoid”：epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26：3063-3072, 2008

2）Partelli S, Bartsch DK, Capdevila J, et al：ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours：Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology 105：255-265, 2017

3）Al-Toubah T, Partelli S, Cives M, et al：Local treatment for focal progression in metastatic neuroendocrine tumors. Endocr Relat Cancer 26：405-409, 2019

4）Howe JR, Merchant NB, Conrad C, et al：The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 49：1-33, 2020

5）Pavel M, O'Toole D, Costa F, et al：ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms（NEN）and NEN of Unknown Primary Site. Neuroendocrinology 103：172-185, 2016

6）Fairweather M, Swanson R, Wang J, et al：Management of Neuroendocrine Tumor Liver Metastases：Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol 24：2319-2325, 2017

7）Woltering EA, Voros BA, Beyer DT, et al：Aggressive Surgical Approach to the Management of Neuroendocrine Tumors：A Report of 1,000 Surgical Cytoreductions by a Single Institution. J Am Coll Surg 224：434-447, 2017

8）Saxena A, Chua TC, Perera M, et al：Surgical resection of hepatic metastases from neuroendocrine neoplasms：a systematic review. Surg Oncol 21：e131-141, 2012

9）Kaçmaz E, Heidsma CM, Besselink MGH, et al：Treatment of Liver Metastases from Midgut Neuroendocrine Tumours：A Systematic Review and Meta-Analysis. J Clin Med 8：403, 2019

10）Yuan CH, Wang J, Xiu DR, et al：Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases. Ann Surg Oncol 23：244-249, 2016

11）Spolverato G, Vitale A, Ejaz A, et al：Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases：A Markov decision model. Surgery 158：339-348, 2015

12）Lesurtel M, Nagorney DM, Mazzaferro V, et al：When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB（Oxford）17：17-22, 2015

13）Partelli S, Cirocchi R, Rancoita PMV, et al：A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB（Oxford）20：197-203, 2018

14）Tierney JF, Chivukula SV, Wang X, et al：Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery 165：644-651, 2019

15）Mazzaferro V, Sposito C, Coppa J, et al：The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant 16：2892-2902, 2016

16）Maekawa A, Kudo A, Kishino M, et al：Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms：a novel therapeutic strategy. J Cancer Res Clin Oncol 2021［Online ahead of print］

17）Pavel M, Baudin E, Couvelard A, et al：ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95：157-176, 2012

18）Modlin IM, Oberg K, Chung DC, et al：Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9：61-72, 2008

19）Dromain C, de Baere T, Lumbroso J, et al：Detection of liver metastases from endocrine tumors：a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23：70-78, 2005

20）Giesel FL, Kratochwil C, Mehndiratta A, et al：Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 81：2820-2825, 2012

21）Strosberg J, El-Haddad G, Wolin E, et al：Phase 3 Trial of. N Engl J Med 376：125-135, 2017

22）Mizuno Y, Kudo A, Akashi T, et al：Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 144：1155-1163, 2018

23）Okuyama H, Ikeda M, Okusaka T, et al：A Phase Ⅱ Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy（NECTOR Trial）. Neuroendocrinology 110：988-993, 2020

24）Shibuya H, Hijioka S, Sakamoto Y, et al：Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan：focus on weekly regimens and monotherapy. Cancer Chemother Pharmacol 82：661-668, 2018

25）Ono H, Kudo A, Akahoshi K, et al：Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 146：793-799, 2020

26）Coriat R, Walter T, Terris B, et al：Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors：Review and Position Statement. Oncologist 21：1191-1199, 2016

27）Lamarca A, Elliott E, Barriuso J, et al：Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis：A lost cause? Cancer Treat Rev 44：26-41, 2016

28）Barber TW, Hofman MS, Thomson BN, et al：The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol 38：64-71, 2012

29）van Vliet EI, van Eijck CH, de Krijger RR, et al：Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with［177Lu-DOTA0, Tyr3］Octreotate. J Nucl Med 56：1647-1653, 2015

30）Asano D, Kudo A, Akahoshi K, et al：Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms. Ann Surg 2020.

31）Murase Y, Kudo A, Akahoshi K, et al：Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms. Ann Gastroenterol Surg 5：692-700, 2021

32）Koea J, Section CNTRCCS. Management of Locally Advanced and Unresectable Small Bowel Neuroendocrine Tumours. World J Surg 45：219-224, 2021